Cohance Lifesciences Ltd (NSE: COHANCE, BSE: 543064) is a Hyderabad, Telangana-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹17,756 Cr, it ranks #395 by market cap among the 6,197 Indian listed companies on FinBizNet, and #5 of 11 in Pharmaceutical CDMO and CRO Services. At ₹459.40 (as of 16 Nov 2026), the share price is 26.4% below its 52-week high of ₹624.00 and 72.3% above its 52-week low of ₹266.70. The share price is down 35.2% over one year and up 3.2% over three months.
| Current Price | ₹459.40 |
|---|---|
| Market Cap | ₹17,756 Cr |
| NSE Symbol | COHANCE |
| BSE Code | 543064 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 100.6 |
| Return on Equity | 5.11% |
| Return on Assets | 2.69% |
| 52-Week Range | ₹266.70 – ₹624.00 |
| 1-Year Price Change | -35.2% |
| 3-Month Price Change | +3.2% |
| Beta (1Y) | 0.36 |
| Dividend Yield | 0.00% |
| Headquarters | Hyderabad, Telangana |
| Website | www.cohance.com |
| Revenue | ₹477 Cr |
|---|---|
| Net Profit | ₹2 Cr |
| Net Margin | 0.5% |
| EPS (Basic) | ₹0.40 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Cohance Lifesciences Ltd reported revenue of ₹477 Cr in Q2 FY27, down 14.2% from ₹556 Cr in Q2 FY26 and up 12.9% from ₹422 Cr in Q1 FY27. It posted a net profit of ₹2 Cr for the quarter, against a net profit of ₹66 Cr in Q2 FY26 (down 96.6%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹402 Cr (Q4 FY25) to ₹619 Cr (Q4 FY26). The company reported a net loss in 1 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹477 Cr | ₹2 Cr | 0.5% |
| Q1 FY27 | ₹422 Cr | −₹45 Cr | −10.7% |
| Q4 FY26 | ₹619 Cr | ₹8 Cr | 1.3% |
| Q3 FY26 | ₹545 Cr | ₹29 Cr | 5.3% |
| Q2 FY26 | ₹556 Cr | ₹66 Cr | 11.9% |
| Q1 FY26 | ₹549 Cr | ₹46 Cr | 8.4% |
| Q4 FY25 | ₹402 Cr | ₹39 Cr | 9.6% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 57.48% of Cohance Lifesciences Ltd's shares as of Sept 2026, against 57.49% in Sept 2025 (−0.01 percentage points). Delivery averaged 42.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
1. Contract Development and Manufacturing Operations (CDMO)-This segment develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services. 2. NA-NA 3. NA-NA 4. NA-NA
1. Contract Development and Manufacturing Operations (CDMO)-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹3,01,758 Cr | 118.4 | 16.19% | ₹3,676 Cr | +71.9% |
| Anthem Biosciences Limited | ₹53,926 Cr | 90.1 | 19.45% | ₹594 Cr | +34.5% |
| Sai Life Sciences Limited | ₹40,755 Cr | 116.1 | 15.13% | ₹659 Cr | +120.3% |
| Onesource Specialty Pharma Limited | ₹18,138 Cr | n/m | -1.26% | ₹516 Cr | -9.4% |
| Cohance Lifesciences Ltd | ₹17,756 Cr | 100.6 | 5.11% | ₹477 Cr | -35.2% |
| Syngene International Ltd. | ₹17,630 Cr | 56.9 | 6.62% | ₹833 Cr | -27.9% |
| Jubilant Pharmova Ltd | ₹15,556 Cr | 39.1 | 5.96% | ₹2,370 Cr | -14.5% |
| Concord Biotech Ltd | ₹12,495 Cr | 24.2 | 13.54% | ₹309 Cr | -14.8% |
| Blue Jet Healthcare Ltd | ₹10,140 Cr | 38 | 19.88% | ₹376 Cr | -9.8% |
Listed by market capitalisation. Ratios are shown for context only.
Cohance Lifesciences Ltd is trading at ₹459.40, with a market capitalisation of ₹17,756 Cr.
Cohance Lifesciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Cohance Lifesciences Ltd has a P/E of 100.6 and a return on equity of 5.11%.
Cohance Lifesciences Ltd is listed on the NSE under the symbol COHANCE and on the BSE under the scrip code 543064.
Cohance Lifesciences Ltd's share price is down 35.2% over one year and up 3.2% over three months. Its 52-week range is ₹266.70 to ₹624.00.
In Q2 FY27, Cohance Lifesciences Ltd reported revenue of ₹477 Cr and net profit of ₹2 Cr, with basic EPS of ₹0.4 (consolidated, parsed from the company's exchange filing).
Cohance Lifesciences Ltd reported revenue of ₹477 Cr in Q2 FY27, down 14.2% from ₹556 Cr in Q2 FY26 and up 12.9% from ₹422 Cr in Q1 FY27.
Promoters held 57.48% of Cohance Lifesciences Ltd's shares as of Sept 2026, against 57.49% in Sept 2025 (−0.01 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.